Fortress Biotech (FBIO)
(Real Time Quote from BATS)
$1.83 USD
-0.04 (-2.14%)
Updated May 28, 2024 11:54 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 1 - 20 ( 315 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: 3 Upcoming Approvals in the Next 9 Months
Provider: Roth Capital Partners, Inc.
Analyst: WITTES J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Several Major Regulatory Approval Milestones Rapidly Approach; Target Increased to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fortress Raises $10M w/Participation by Directors/Officers. Adjusting for Dilution we Lower Our Price Target from $12 to $10.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reverse Stock Split 1:15, Price Target Set to $12.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Updated Model - Monetizations Could Restart in 2024
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: The Hits Just Keep Comin? Checkpoint Releases Promising Data in Advanced Cutaneous Cell Carcinoma
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J